Skip NavigationSkip to Content
Return Return to Search Results

Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection

  1. Author:
    Walker, Stephanie M
    Mehralivand, Sherif
    Harmon,Stephanie
    Sanford, Thomas
    Merino, Maria J
    Wood, Bradford J
    Shih, Joanna H
    Pinto, Peter A
    Choyke, Peter L
    Turkbey, Baris

  2. Author Address

    Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm B3B85, Bethesda, MD 20892., Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Bethesda, MD., Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD., Center for Interventional Oncology, National Cancer Institute, Bethesda, MD., Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD., Biometric Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.,
    1. Year: 2020
    2. Date: NOV
    3. Epub Date: 2020 09 02
  2. Journal: AJR. American journal of roentgenology
    1. 215
    2. 5
    3. Pages: 1098-1103
  4. Type of Article: Article
  5. ISSN: 0361-803X
  1. Abstract:

    OBJECTIVE. The purpose of this study was to prospectively evaluate Prostate Imaging Reporting and Data and System version 2.1 (PI-RADSv2.1), which was released in March 2019 to update version 2.0, for prostate cancer detection with transrectal ultrasound-MRI fusion biopsy and 12-core systematic biopsy. SUBJECTS AND METHODS. This prospective study included 110 consecutively registered patients who underwent multiparametric MRI evaluated with PI-RADSv2.1 criteria followed by fusion biopsy and systematic biopsy between April and September 2019. Lesion-based cancer detection rates (CDRs) were calculated for prostate cancer (Gleason grade group, > 0) and clinically significant prostate cancer (Gleason grade group, > 1). RESULTS. A total of 171 lesions (median size, 1.1 cm) in 110 patients were detected and evaluated with PI-RADSv2.1. In 16 patients no lesion was detected, and only systematic biopsy was performed. Lesions were categorized as follows: PI-RADS category 1, 1 lesion; PI-RADS category 2, 34 lesions; PI-RADS category 3, 54 lesions; PI-RADS category 4, 52 lesions; and PI-RADS category 5, 30 lesions. Histopathologic analysis revealed prostate cancer in 74 of 171 (43.3%) lesions and clinically significant prostate cancer in 57 of 171 (33.3%) lesions. The CDRs of prostate cancer for PI-RADS 2, 3, 4, and 5 lesions were 20.0%, 24.1%, 51.9%, and 90.0%. The CDRs of clinically significant prostate cancer for PI-RADS 1, 2, 3, 4, and 5 lesions were 0%, 5.7%, 14.8%, 44.2%, and 80.0%. In 16 patients with normal multiparametric MRI findings (PI-RADS 1), the CDRs were 50.0% for PCa and 18.8% for clinically significant prostate cancer. CONCLUSION. This investigation yielded CDRs assessed with prospectively assigned PI-RADSv2.1 scores. CDRs increased with higher PI-RADSv2.1 scores. These results can be compared with previously published outcomes derived with PI-RADS version 2.0.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.2214/AJR.19.22679
  3. PMID: 32877244
  4. View record in Web of Science®
  5. WOS: 000582043500018

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel